|Trade names||Wokadine, Pyodine, Betadine, others|
|AHFS/Drugs.com||International Drug Names|
|Synonyms||polyvidone iodine, iodopovidone|
|Chemical and physical data|
|(what is this?)|
Povidone-iodine (PVP-I), also known as iodopovidone, is an antiseptic used for skin disinfection before and after surgery. It may be used both to disinfect the skin of the patient and the hands of the healthcare providers. It may also be used for minor wounds. It may be applied to the skin as a liquid or a powder.
Side effects include skin irritation. If used on large wounds kidney problems, high blood sodium, and metabolic acidosis may occur. It is not recommended in people who are less than 32 weeks pregnant or are taking lithium. Frequent use is not recommended in people with thyroid problems. Povidone-iodine is a chemical complex of povidone and the element iodine. It contains from 9% to 12% available iodine. It works by releasing iodine which results in the death of a range of microorganisms.
Povidone-iodine came into commercial use in 1955. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Providone-iodine is available over the counter. The wholesale cost in the developing world is about 3.30 to 11.40 USD per liter of 10% solution. This amount in the United Kingdom cost the NHS about 10.86 pounds. It is sold under a number of brand names including Betadine.
Povidone-iodine is a broad spectrum antiseptic for topical application in the treatment and prevention of wound infection. It may be used in first aid for minor cuts, grazes, burns, abrasions and blisters. Povidone-iodine exhibits longer lasting antiseptic effects than tincture of iodine, due to its slow absorption via soft tissue, making it the choice for longer surgeries. Chlorhexidine provides similar results, but with no toxicity concerns.
Bacteria do not develop resistance to PVP-I.
Consequently, PVP-I has found broad application in medicine as a surgical scrub; for pre- and post-operative skin cleansing; for the treatment and prevention of infections in wounds, ulcers, cuts and burns; for the treatment of infections in decubitus ulcers and stasis ulcers; in gynecology for vaginitis associated with candidal, trichomonal or mixed infections. For these purposes PVP-I has been formulated at concentrations of 7.5–10.0% in solution, spray, surgical scrub, ointment, and swab dosage forms.
2.5% buffered PVP-I solution can be used for prevention of neonatal conjunctivitis, especially if it is caused by Neisseria gonorrhoeae, or Chlamydia trachomatis. It is currently unclear whether PVP-I is more effective in reducing the incidence of conjunctivitis in neonates over other methods. PVP-I appears to be very suitable for this purpose because, unlike other substances, it is also efficient against fungi and viruses (including HIV and Herpes simplex).
It is used in pleurodesis (fusion of the pleura because of incessant pleural effusions). For this purpose, povidone-iodine is equally effective and safe as talc, and may be preferred because of easy availability and low cost.
There is tentative evidence that chlorhexidine and denatured alcohol use to clean skin prior to surgery is better than povidone-iodine with alcohol; however, the evidence is not strong enough as of 2015 to determine routine practice.
PVP-I is contraindicated in patients with hyperthyroidism (overactive thyroid gland) and other diseases of the thyroid, after treatment with radioiodine, and in patients with dermatitis herpetiformis[why?] (Duhring's disease).
The iodine in PVP-I reacts with hydrogen peroxide, silver, taurolidine and proteins such as enzymes, rendering them (and itself) ineffective. It also reacts with many mercury compounds, giving the corrosive compound mercury iodide, as well as with many metals, making it unsuitable for disinfecting metal piercings.
Iodine is absorbed into the body to various degrees, depending on application area and condition of the skin. As such, it interacts with diagnostic tests of the thyroid gland such as radioiodine diagnostics, as well as with various diagnostic agents used on the urine and stool, for example Guaiacum resin.
PVP-I is completely soluble in cold and mild-warm water, ethyl alcohol, isopropyl alcohol, polyethylene glycol, and glycerol. Its stability in solution is much greater than that of tincture of iodine or Lugol's solution.
Free iodine, slowly liberated from the povidone-iodine (PVP-I) complex in solution, kills eukaryotic or prokaryotic cells through iodination of lipids and oxidation of cytoplasmic and membrane compounds. This agent exhibits a broad range of microbicidal activity against bacteria, fungi, protozoa, and viruses. Slow release of iodine from the PVP-I complex in solution minimizes iodine toxicity towards mammalian cells.
PVP-I can be loaded into hydrogels, which can be based on carboxymethyl cellulose (CMC), poly(vinyl alcohol) (PVA), and gelatin, or on crosslinked polyacrylamide. These hydrogels can be used for wound dressing. The rate of release of the iodine in the PVP-I is heavily dependent on the hydrogel composition: it increases with more CMC/PVA and decreases with more gelatin.
It was discovered in 1955 at the Industrial Toxicology Laboratories in Philadelphia by H. A. Shelanski and M. V. Shelanski. They carried out tests in vitro to demonstrate anti-bacterial activity, and found that the complex was less toxic in mice than tincture of iodine. Human clinical trials showed the product to be superior to other iodine formulations.
Following the discovery of iodine by Bernard Courtois in 1811, it has been broadly used for the prevention and treatment of skin infections, as well as the treatment of wounds. Iodine has been recognized as an effective broad-spectrum bactericide, and is also effective against yeasts, molds, fungi, viruses, and protozoans. Drawbacks to its use in the form of aqueous solutions include irritation at the site of application, toxicity, and the staining of surrounding tissues. These deficiencies were overcome by the discovery and use of PVP-I, in which the iodine is carried in a complexed form and the concentration of free iodine is very low. The product thus serves as an iodophor.
Povidone-iodine has found application in the field of nanomaterials. A wound-healing application has been developed which employs a mat of single wall carbon nanotubes (SWNTs) coated in a monolayer of povidone-iodine.
Research has previously found that the polymer polyvinylpyrrolidone (PVP, povidone) can coil around individual carbon nanotubes to make them water-soluble.
- WHO Model Formulary 2008 (PDF). World Health Organization. 2009. pp. 321–323. ISBN 9789241547659. Retrieved 8 January 2017.
- British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 840. ISBN 9780857111562.
- Encyclopedia of polymer science and technology (3 ed.). John Wiley & Sons. 2013. p. 728. ISBN 9780470073698.
- Sneader, Walter (2005). Drug Discovery: A History. John Wiley & Sons. p. 68. ISBN 9780470015520.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
- "Povidone/iodine solution: Indications, Side Effects, Warnings - Drugs.com". www.drugs.com. Retrieved 11 January 2017.
- "Povidone iodine". International Drug Price Indicator Guide. Retrieved 8 December 2016.
- Fleischer, W.; Reimer, K. (1997). "Povidone-iodine in antisepsis — State of the art". Dermatology. 195 (Suppl 2): 3–9. doi:10.1159/000246022.
- Kapoor VS, Whyte R, Vedula SS (2016). "Interventions for preventing ophthalmia neonatorum". Cochrane Database Syst Rev. 9: CD001862. doi:10.1002/14651858.CD001862.pub3.
- Najafi Bi, R.; Samani, S. M.; Pishva, N.; Moheimani, F. (2003). "Formulation and Clinical Evaluation of Povidone-Iodine Ophthalmic Drop". Iranian Journal of Pharmaceuticical Research. 2 (3): 157–160.
- Agarwal, R; Khan, A; Aggarwal, AN; Gupta, D (March 2012). "Efficacy & safety of iodopovidone pleurodesis: a systematic review & meta-analysis.". The Indian journal of medical research. 135: 297–304. PMID 22561614.
- Dumville, JC; McFarlane, E; Edwards, P; Lipp, A; Holmes, A; Liu, Z (21 April 2015). "Preoperative skin antiseptics for preventing surgical wound infections after clean surgery.". The Cochrane database of systematic reviews (4): CD003949. PMID 25897764.
- Jasek, W, ed. (2007). Austria-Codex (in German) (62nd ed.). Vienna: Österreichischer Apothekerverlag. pp. 983–5. ISBN 978-3-85200-181-4.
- Niedner, R. (1997). "Cytotoxicity and sensitization of povidone-iodine and other frequently used anti-infective agents". Dermatology. 195 (Suppl 2): 89–92. doi:10.1159/000246038.
- U.S.patent 2,739,922
- Sneader, Walter (2005). Drug Discovery: A History. New York: John Wiley & Sons. p. 68. ISBN 0-471-89979-8.
- Simmons, Trevor; Lee, S.-H.; Park, T.-J.; Hashim, D.P.; Ajayan, P.M.; Linhardt, R.J. (2009). "Antiseptic Single Wall Carbon Nanotube Bandages" (PDF). Carbon. 47 (6): 1561–1564. doi:10.1016/j.carbon.2009.02.005.
- Simmons, Trevor; Hashim, D; Vajtai, R; Ajayan, PM (2007). "Large Area-Aligned Arrays from Direct Deposition of Single-Wall Carbon Nanotubes". J. Am. Chem. Soc. 129 (33): 10088–10089. doi:10.1021/ja073745e. PMID 17663555.
- Randolph H.L. Wong; Emily C.W. Hung; Vivien W.Y. Wong; Innes Y.P. Wan; Calvin S.H. Ng; Song Wan; Malcolm J. Underwood (2009). "Povidone-iodine wound irrigation: A word of caution". Surgical Practice. 13 (4): 123–4. doi:10.1111/j.1744-1633.2009.00461.x.
- Randolph H.L. Wong; Vivien W.Y. Wong; Emily C.W. Hung; Ping Yin Lee; Calvin S.H. Ng; Innes Y.P. Wan; Song Wan; Malcolm J. Underwood (2011). "Topical application of povidone-iodine before wound closure is associated with significant increase in serum iodine level". Surgical Practice. 19: 79–82.
- Randolph H.L. Wong; Calvin S.H. Ng; Malcolm J. Underwood (2011). "Iodine pleurodesis--a word of caution". European Journal of Cardio-Thoracic Surgery. 41 (5): 1209. doi:10.1093/ejcts/ezr137.